Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers

PURPOSE: Recommendations for treating patients who carry a BRCA1/2 gene are mainly based on cumulative lifetime risks (CLTRs) of breast cancer determined from retrospective cohorts. These risks vary widely (27% to 88%), and it is important to understand why. We analyzed the effects of methods of ris...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Vos, Janet R., Hsu, Li, Brohet, Richard M., Mourits, Marian J.E., de Vries, Jakob, Malone, Kathleen E., Oosterwijk, Jan C., de Bock, Geertruida H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2015
Soggetti:
Review Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979233/
https://ncbi.nlm.nih.gov/pubmed/26150446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.0463
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi